These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 21654386)

  • 1. New therapeutic targets and drugs in non-Hodgkin's lymphoma.
    Sawas A; Diefenbach C; O'Connor OA
    Curr Opin Hematol; 2011 Jul; 18(4):280-7. PubMed ID: 21654386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mantle cell lymphoma in relapse: the role of emerging new drugs.
    Diefenbach CS; O'Connor OA
    Curr Opin Oncol; 2010 Sep; 22(5):419-23. PubMed ID: 20679769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
    Jazirehi AR; Bonavida B
    Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Signal transduction inhibitors in chronic lymphocytic leukemia.
    Ma S; Rosen ST
    Curr Opin Oncol; 2011 Nov; 23(6):601-8. PubMed ID: 21892084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.
    Delmonte A; Ghielmini M; Sessa C
    Oncologist; 2009 May; 14(5):511-25. PubMed ID: 19411316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
    Zhao WL; Wang L; Liu YH; Yan JS; Leboeuf C; Liu YY; Wu WL; Janin A; Chen Z; Chen SJ
    Exp Hematol; 2007 Dec; 35(12):1801-11. PubMed ID: 17681667
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging protein kinase inhibitors for the treatment of non-Hodgkin's lymphoma.
    Jahangiri S; Friedberg J; Barr P
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):367-83. PubMed ID: 24960458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma.
    Rodgers TD; Reagan PM
    Expert Opin Emerg Drugs; 2018 Jun; 23(2):111-122. PubMed ID: 29781323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging therapies for B-cell non-Hodgkin lymphoma.
    Briones J
    Expert Rev Anticancer Ther; 2009 Sep; 9(9):1305-16. PubMed ID: 19761434
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An overview of investigational Histone deacetylase inhibitors (HDACis) for the treatment of non-Hodgkin's lymphoma.
    Apuri S; Sokol L
    Expert Opin Investig Drugs; 2016 Jun; 25(6):687-96. PubMed ID: 26954526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of the Raf-MEK1/2-ERK1/2 signaling pathway, Bcl-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B cells by Rituximab.
    Jazirehi AR; Vega MI; Chatterjee D; Goodglick L; Bonavida B
    Cancer Res; 2004 Oct; 64(19):7117-26. PubMed ID: 15466208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination antibody therapy with epratuzumab and rituximab in relapsed or refractory non-Hodgkin's lymphoma.
    Leonard JP; Coleman M; Ketas J; Ashe M; Fiore JM; Furman RR; Niesvizky R; Shore T; Chadburn A; Horne H; Kovacs J; Ding CL; Wegener WA; Horak ID; Goldenberg DM
    J Clin Oncol; 2005 Aug; 23(22):5044-51. PubMed ID: 15955901
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New drugs and targeted treatments in Hodgkin's lymphoma.
    Provencio M; Sánchez A; Sánchez-Beato M
    Cancer Treat Rev; 2014 Apr; 40(3):457-64. PubMed ID: 24095205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase inhibitors in lymphoma.
    Copeland A; Buglio D; Younes A
    Curr Opin Oncol; 2010 Sep; 22(5):431-6. PubMed ID: 20683267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 16. B-cell receptor pathobiology and targeting in NHL.
    Macias-Perez IM; Flinn IW
    Curr Oncol Rep; 2012 Oct; 14(5):411-8. PubMed ID: 22865093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance.
    Vega MI; Huerta-Yepaz S; Garban H; Jazirehi A; Emmanouilides C; Bonavida B
    Oncogene; 2004 Apr; 23(20):3530-40. PubMed ID: 15077178
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Conventional treatments for non-Hodgkin's lymphoma: the need for new therapies.
    Moskowitz CH
    J Nucl Med; 1998 Aug; 39(8 Suppl):2S-10S. PubMed ID: 9708564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pixantrone for the treatment of aggressive non-Hodgkin lymphoma.
    Mukherji D; Pettengell R
    Expert Opin Pharmacother; 2010 Aug; 11(11):1915-23. PubMed ID: 20569087
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.